Drug Dealer | search
Click here to view Drug Dealer news from 60+ newspapers.
Bookmark or Share- Full study data back Alnylam heart drug’s benefit, but leave doctors ...Another drug, called acoramidis and from BridgeBio Pharma, could be approved later this year. Multiple other treatments are in advanced testing. Among the new information from Helios-B disclosed Friday was a more detailed accounting of how vutrisiran’s benefit evolved over time.
- Eli Lilly adds ALS drug prospect with QurAlis dealEli Lilly adds ALS drug prospect with QurAlis deal. Lilly will pay the startup $45 million upfront for an RNA-based therapy in early development, and begin a research collaboration to unearth other, similar medicines. The Lilly Biotechnology Center is seen in San Diego, California. JHVEPhoto via Getty Images.
- Bristol Myers pays $100M for a different kind of ADCUnder the terms of the deal, Bristol Myers will pay Orum $100 million for the program and commit to paying as much as $80 million more if certain milestones are met. Orum describes its therapy, dubbed ORM-6151, as an antibody-enabled protein degrader, merging the concept of an antibody-drug conjugate with the field of protein degradation.
- Sanofi’s rare disease drug finds yet another homeBy 2017, it had been snapped up by Biogen’s hemophilia-focused spin off Bioverativ. John Cox, the then-CEO of Bioverativ, said at the time that Enjaymo was a central asset in the deal and filled an important gap in the company’s research efforts. Enjaymo, however, would move to yet another owner in 2018, when Sanofi bought Bioverativ for ...
- FDA approves Merck lung disease drug acquired in $11B dealMerck acquired Winrevair through an $11.5 billion buyout of Acceleron Pharma in 2021. It’s part of a pipeline that the New Jersey-based drumaker estimates will bring in $35 billion in annual sales by the middle of the next decade. Winrevair will be available in either a 45 milligram or 60 milligram vial, each costing $14,000 apiece.
More
